Pfizer's one-time gene therapy for Duchenne muscular dystrophy has failed to improve the motion function of patients in a Phase 3 clinical trial.
The gene therapy, called CIFFREO, delivered a shortened version of the missing human dystrophin gene to Duchenne muscular dystrophy patient's cells.
Read more in Reuters.
Related Articles
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
Gene therapy stops, and may reverse, muscular dystophy in mice
A gene therapy for Duchenne muscular dystrophy has halted the muscle decline associated with the condition in mice, and has also shown promise at repairing the muscles...
